# A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

> **NCT04671771** · NA · RECRUITING · sponsor: **W.L.Gore & Associates** · enrollment: 133 (estimated)

## Conditions studied

- End Stage Renal Disease (ESRD)
- Kidney Failure
- Chronic Renal Disease
- Hemodialysis

## Interventions

- **DEVICE:** InnAVasc Arteriovenous Graft (IG) surgical implant

## Key facts

- **NCT ID:** NCT04671771
- **Lead sponsor:** W.L.Gore & Associates
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-03
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671771, "A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04671771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*